Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus ZYRTEC.
SEMPREX-D vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine